RYTM - Rhythm Pharmaceuticals: Opportunity To Take Position Ahead Of Pivotal Data
Shares of Rhythm Pharmaceuticals (RYTM) have finished essentially flat, since my October 2017 article suggested that initial encouraging clinical data for drug candidate setmelanotide was just the beginning. On the other hand, the stock has performed admirably (up about 50%) since its $17 IPO pricing a couple years back.
While investors here haven't been rewarded since my initial article, I'm looking forward to revisiting the story ahead of phase 3 readouts late in 2019.
Chart
Figure 1: RYTM daily advanced chart (Source: Finviz)
Figure 2: RTYM 15-minute chart (Source: Finviz)
When looking at